[Blog] Traceability of Medicines in Indonesia: Regulatory Requirements, Timelines, and Compliance Strategy
Table of Contents
Traceability of Medicines in Indonesia: Regulatory Requirements and Compliance
Indonesia represents one of the most dynamic pharmaceutical markets in Southeast Asia. With a population of nearly 280 million and expanding access to healthcare, the market was valued at approximately USD 7–8 billion in 2020 and is projected to exceed USD 11 billion by the mid-2020s. Growth is driven by both prescription medicines and over-the-counter (OTC) products.
At the same time, counterfeit and illegally distributed medicines continue to pose a material public health risk. Industry and regulatory estimates indicate that counterfeit products have historically represented around 3–5% of the pharmaceutical market, with higher exposure in specific therapeutic categories and online distribution channels. These products may contain incorrect, insufficient, or harmful ingredients, directly compromising patient safety and treatment outcomes.
To address these risks, Indonesia has accelerated the implementation of a national medicine traceability framework. Through barcode-based identification, serialization, aggregation, and centralized reporting, the country aims to strengthen supply chain transparency and systematically reduce counterfeiting.
Regulatory Authorities and Legal Framework
- Indonesia National Agency of Drug and Food Control (BPOM)
- Ministry of Health (Kementerian Kesehatan)
Core Legislation
- BPOM Regulation No. 22/2022 – Implementation of 2D Barcode in Drug and Food Monitoring
- Effective date: 5 October 2022
Indonesia Traceability Requirements for Medicines
Indonesia’s traceability framework is built around two complementary barcode layers: Identification and Authentication.
Identification Barcode (QR Code)
Purpose
- Product identification
- Verification of legality
- Access to consumer and regulatory information
Status
- Mandatory and already in force
Scope
The Identification QR Code is required on all BPOM-regulated products, including:
- Over-the-counter (OTC) medicines
- Traditional medicines (Jamu and herbal products)
- Health supplements
- Cosmetics
- Processed foods
- Biological products and vaccines (at identification level)
Authentication Barcode (GS1 2D DataMatrix)
- Anti-counterfeiting
- Pack-level authentication
- End-to-end traceability
- Phased mandatory implementation
Required for all finished pharmaceutical products manufactured in or imported into Indonesia in the following category:
- Narcotics and psychotropics
- All prescription (“hard”) medicines, including biological products
- Radiopharmaceuticals and contrast media
- Medicines distributed under emergency use authorization or special access schemes
Implementation Timeline
- Narcotics
- Psychotropics
- Selected controlled or high-risk prescription medicines (as defined by BPOM)
Phase 2 – Deadline: 7 December 2027
Mandatory for:
- All prescription medicines
- Biological products and biologics
Serialization and Data Standards
- Unique serial number per saleable unit
- GS1-compliant 2D DataMatrix on each pack
- Product Distribution Permit Number (NIE) – AI (90), up to 16 alphanumeric characters
- and/or
- GTIN – AI (01), up to 14 numeric characters
- Batch/Lot Number – AI (10), 1–20 alphanumeric characters
- Expiry Date – AI (17), 6 numeric characters (YYMMDD)
- Unique Serial Number – AI (21), 1–20 alphanumeric characters
Aggregation Requirements
- GTIN – product identification
- SSCC – logistic units (cartons, cases, pallets)
- GS1 2D DataMatrix on saleable units
- GS1-128 barcodes on logistic units
Centralized Reporting to BPOM (TTAC System)
- Manufacturers and Marketing Authorization Holders (MAHs)
- Importers
For serialized products, reporting typically includes:
Product Master Data
- GTIN
- BPOM marketing authorization number
Serialization Data
- Unique serial numbers
- Batch/lot numbers
- Expiry dates
Aggregation Data
- Parent–child relationships (unit → carton → case → pallet)
Transaction and Event Data
- Release for sale
- Shipment and receipt events
- Returns, decommissioning, and destruction (where applicable)
Final Considerations for Pharmaceutical Companies
Indonesia’s traceability framework is moving rapidly toward full serialization and end-to-end visibility for prescription medicines. While deadlines extend to 2027, implementation complexity—particularly around aggregation, data quality, and system integration—requires early preparation.
For manufacturers, MAHs, and importers, compliance is no longer a packaging-only exercise. It is a data-driven, system-integrated process that directly impacts operational continuity, market access, and regulatory confidence.
A scalable, standards-based serialization and reporting architecture is essential to meet BPOM requirements today and remain adaptable as Indonesia’s traceability ecosystem continues to evolve.
Indonesia’s pharmaceutical traceability system requires barcode-based identification, GS1 DataMatrix serialization, aggregation, and centralized reporting to BPOM’s TTAC platform.
Preparing for BPOM serialization deadlines requires more than barcodes. A compliant traceability architecture must scale with data, aggregation, and reporting requirements. Read more >>